SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Caplan AI, Bruder SP. Mesenchymal stem cells: Building blocks for molecular medicine in the 21st century. Trends Mol Med 2001; 7: 259264.
  • 2
    Pei L, Tontonoz P. Fat's loss is bone's gain. J Clin Invest 2004; 113: 805806.
  • 3
    Gimble JM, Zvonic S, Floyd ZE et al. Playing with bone and fat. J Cell Biochem 2006; 98: 251266.
  • 4
    Hofbauer LC, Brueck CC, Singh SK et al. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007; 22: 13171328.
  • 5
    Rosen CJ, Bouxsein ML. Mechanisms of disease: Is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006; 2: 3543.
  • 6
    Duque G. Bone and fat connection in aging bone. Curr Opin Rheumatol 2008; 20: 429434.
  • 7
    Zhao LJ, Jiang H, Papasian CJ et al. Correlation of obesity and osteoporosis: Effect of fat mass on the determination of osteoporosis. J Bone Miner Res 2008; 23: 1729.
  • 8
    Oh KW, Lee WY, Rhee EJ et al. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf) 2005; 63: 131138.
  • 9
    Ducy P, Amling M, Takeda S et al. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000; 100: 197207.
  • 10
    Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 17841792.
  • 11
    Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 8489.
  • 12
    Yatagai T, Nagasaka S, Taniguchi A et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 2003; 52: 12741278.
  • 13
    Takemura Y, Ouchi N, Shibata R et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007; 117: 375386.
  • 14
    Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762769.
  • 15
    Yoon MJ, Lee GY, Chung JJ et al. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 2006; 55: 25622570.
  • 16
    Luo XH, Guo LJ, Yuan LQ et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005; 309: 99109.
  • 17
    Raisz LG. Prostaglandins and bone: Physiology and pathophysiology. Osteoarthritis Cartilage 1999; 7: 419421.
  • 18
    Jee WS, Ma YF. The in vivo anabolic actions of prostaglandins in bone. Bone 1997; 21: 297304.
  • 19
    Weinreb M, Suponitzky I, Keila S. Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone 1997; 20: 521526.
  • 20
    Forwood MR. Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 1996; 11: 16881693.
  • 21
    Zhang X, Schwarz EM, Young DA et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109: 14051415.
  • 22
    Berner HS, Lyngstadaas SP, Spahr A et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004; 35: 842849.
  • 23
    Yokota T, Meka CS, Medina KL et al. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest 2002; 109: 13031310.
  • 24
    Lee HW, Suh JH, Kim HN et al. Berberine promotes osteoblast differentiation by Runx2 activation with p38 MAPK. J Bone Miner Res 2008; 23: 12271237.
  • 25
    Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: Potential molecular targets for chemoprevention. Biochem Pharmacol 2004; 68: 10891100.
  • 26
    Bannister AJ, Oehler T, Wilhelm D et al. Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. Oncogene 1995; 11: 25092514.
  • 27
    Musti AM, Treier M, Bohmann D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 1997; 275: 400402.
  • 28
    Yamagishi S, Yamada M, Ishikawa Y et al. p38 mitogen-activated protein kinase regulates low potassium-induced c-Jun phosphorylation and apoptosis in cultured cerebellar granule neurons. J Biol Chem 2001; 276: 51295133.
  • 29
    Zaidi SK, Sullivan AJ, van Wijnen AJ et al. Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci U S A 2002; 99: 80488053.
  • 30
    Arikawa T, Omura K, Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 2004; 200: 400406.
  • 31
    Afzal F, Pratap J, Ito K et al. Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol 2005; 204: 6372.
  • 32
    Chikazu D, Li X, Kawaguchi H et al. Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: Role in effects of bone morphogenetic protein 2 in vitro and in vivo. J Bone Miner Res 2002; 17: 14301440.
  • 33
    Mehrotra M, Saegusa M, Voznesensky O et al. Role of Cbfa1/Runx2 in the fluid shear stress induction of COX-2 in osteoblasts. Biochem Biophys Res Commun 2006; 341: 12251230.
  • 34
    Shinoda Y, Yamaguchi M, Ogata N et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006; 99: 196208.
  • 35
    Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456469.
  • 36
    Ferron M, Hinoi E, Karsenty G et al. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 2008; 105: 52665270.
  • 37
    Oshima K, Nampei A, Matsuda M et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005; 331: 520526.
  • 38
    Lenchik L, Register TC, Hsu FC et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 2003; 33: 646651.
  • 39
    Paralkar VM, Grasser WA, Mansolf AL et al. Regulation of BMP-7 expression by retinoic acid and prostaglandin E(2). J Cell Physiol 2002; 190: 207217.
  • 40
    Shibata R, Sato K, Pimentel DR et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11: 10961103.
  • 41
    Ikeda Y, Ohashi K, Shibata R et al. Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FEBS Lett 2008; 582: 11471150.
  • 42
    Schroeder TM, Jensen ED, Westendorf JJ. Runx2: A master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today 2005; 75: 213225.